biostudies-literatureUnknown2025Lin KHPatients with chronic lymphocytic leukemia (CLL) treated with covalent Bruton's tyrosine kinase inhibitors (BTKi) eventually discontinue treatment, but data on outcomes post-BTKi treatment discontinuation are limited. In this single-institution, retrospective chart review of 104 adult patients with CLL treated with a covalent BTKi between July 2011 and April 2019 and who subsequently discontinued for any reason, the majority of patients (59.9%) received the index BTKi in their first (27.5%) or second (32.4%) line of therapy. Median progression-free survival (PFS) from index BTKi initiation was 3.2 years, and median overall survival (OS) was 8.9 years. There was a notable correlation between PFS and OS (<i>r</i> = 0.79). Following the discontinuation of their last BTKi treatment, over half Advances in hematology7492594https://www.ebi.ac.uk/biostudies/studies/S-EPMC12665162biostudies-literatureClinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center.PMC12665162Yang XGandra SRZanardo EFarooqui MZHDuh MSLin KHHuynh LDavids MSLiborski DDe Nigris EMcDonough MMBrown JRfalseClinical Outcomes in Patients With CLL Treated With BTKi at a Large US Cancer Center.Patients with chronic lymphocytic leukemia (CLL) treated with covalent Bruton's tyrosine kinase inhibitors (BTKi) eventually discontinue treatment, but data on outcomes post-BTKi treatment discontinuation are limited. In this single-institution, retrospective chart review of 104 adult patients with CLL treated with a covalent BTKi between July 2011 and April 2019 and who subsequently discontinued for any reason, the majority of patients (59.9%) received the index BTKi in their first (27.5%) or second (32.4%) line of therapy. Median progression-free survival (PFS) from index BTKi initiation was 3.2 years, and median overall survival (OS) was 8.9 years. There was a notable correlation between PFS and OS (<i>r</i> = 0.79). Following the discontinuation of their last BTKi treatment, over half 2025-01-01T00:00:00Z20252026-06-06T07:19:00.498Z2026-06-06T03:06:50.029ZS-EPMC126651624132821510.1155/ah/7492594